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Aims: Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with
cisplatin-based chemoradiotherapy. Since it is known that folate metabolism might interfere with cisplatin
effectiveness, we intended to study the inﬂuence of the Gamma Glutamyl Hydrolase -401C>T polymorphism
in treatment response in cervical cancer.
Methods: We retrospectively reviewed the clinical data of 167 patients with bulky cervical cancer submitted
to cisplatin-based chemoradiotherapy. The genotypes of GGH -401C>T SNP were determined by real-time
PCR and statistical analysis was performed by χ2 test and survival analysis.
Results: The genotypes of GGH-401C>T were signiﬁcantly associated with the response to platinum-based
chemoradiotherapy. Treatment response was higher in patients carrying the CC genotype, who presented a
signiﬁcant increased chance of treatment response (survival time in months/genotype: 91 for CC Vs 72 for
CT/TT; p=0.035, log rank test). A Cox regression analysis accordingly showed that the presence of the T al-
lele was signiﬁcantly linked to a worse treatment response (HR=3.036; CI 95% 1.032-8.934, p=0.044).
Conclusions: The results of our study suggested the potential interest of GGH -401C>T as a predictive factor of
the outcome of cervical carcinoma treated with cisplatin-based chemoradiotherapy.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cervical carcinoma was the third most common cancer in women
in 2008. Since it is a platinum-sensitive disease, cisplatin-based
chemoradiotherapy is the standard of care for advanced cervical
cancer stages (IB2-IVA FIGO stages) (Candelaria et al., 2006; Ferlay
et al., 2010; Tewari and Monk, 2010). Although weekly cisplatin at
40 mg/m2 for six weeks is the standard of care for locally advanced
cervical carcinoma inmany cancer centers as ours, its optimal scheduling
and dosing have yet to be established due to the frequent development
of therapy resistance (Candelaria et al., 2006). Different mechanisms, cytosine; T, thymine; SNP,
ederation of Gynecology and
ria in solid tumors; PCR, poly-
atistical packages for the social
rd deviation; HR, hazard ratio;
Oncology, Molecular Oncology
eida, 4200-072 Porto, Portugal.
. Medeiros).
rights reserved.have been proposed to reduce cisplatin response, including altered
drug accumulation, enhanced drug detoxiﬁcation and DNA repair, or
upregulation of speciﬁc biochemical pathways (Ottone et al., 1997;
Siddik, 2003). Thus, the identiﬁcation ofmolecular predictors of response
urges (Siddik, 2003). As patients genetic background might change the
response, metabolism and toxicity of cytotoxic agents as cisplatin (Le et
al., 2005; Siddik, 2003), polymorphisms of genes coding enzymes in-
volved in drug or cellmetabolism aswell as theDNA synthesis and repair
have been studied (Kim et al., 2008).
Due to the synergism between alkylating radiosensitive agents
and radiotherapy, it is possible to get good local and systemic control
rates. However, what is the impact of molecular modulators on each
treatment modality on cervical cancer is still controversial.
GGH is a lysossomal enzyme that regulates intracellular folate
pools and folate metabolism homeostasis (Odin et al., 2003;
Organista-Navaa et al., 2010; Schneider and Ryan, 2006; Yin et
al., 2003). The GGH −401 C>T SNP, which is one of its most com-
mon polymorphisms, is a promoter polymorphism that causes the loss
of an inhibitory transcription-factor binding-site. Due to its inﬂuence on
one-carbonmetabolism and cell survival, its role in cervical carcinogen-
esis and treatment response is biologically plausible (Odin et al., 2003).
Table 1
Sample characterization.
Variables N (%)
Smoking habits
Yes 23 15.5
No 115 77.7
Unknown 10 6.8
Oral contraceptives
Yes 70 45.5
No 70 45.5
Unknown 14 9
Tumor FIGO stage
IB2 13 7.6
IIA 4 2.4
IIB 43 32.6
IIIA 2 1.2
IIIB 20 11.6
IVA 2 1.2
Histology
Squamous cell carcinoma 139 80.3
Adenocarcinoma 22 12.7
Adenosquamous 7 4.0
Others 5 2.9
Lymph node metastasis
Yes 7 5.9
No 112 94.1
Number of chemotherapy cycles completed
1-3 6 3.7
4-6 151 83.5
Treatment response
CR 123 71.9
PR 29 17.0
SD 9 5.3
DP 6 3.5
CR: complete response; PR: partial response; SD: stable disease; DP: disease
progression.
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401 C>T polymorphism in determining chemoradiotherapy response
in cervical cancer.
2. Subjects and Methods
2.1. Subjects
We conducted an hospital-based retrospective study analyzing 167
Caucasian women from Northern Portugal with histologically con-
ﬁrmed cervical cancer IB2-IVA FIGO stages, admitted in the Portuguese
Institute of Oncology, Porto, Portugal. All womenwere treatedwith ﬁrst
line cisplatin-based chemoradiotherapy in the Portuguese Institute of
Oncology from Porto. Assessment of tumor stage was based on the
FIGO system. All samples were obtained with the informed consent of
the participants prior to their inclusion in the study, according to the
declaration of Helsinki.
2.2. Concurrent chemoradiotherapy treatment
Chemotherapy regimen consisted of cisplatin (40 mg/m2, iv) admin-
istered weekly in a total of six weeks. Concurrent radiotherapy consisted
of pelvic external beam radiotherapy (for a total dose of 45–50 Gy of pel-
vic irradiation) andone to three intracavitary brachytherapy applications
after the completion of external pelvic radiotherapy (cumulative dose at
point A: 75 Gy; cumulative dose to point B: 55 Gy). For patients with
lymph node metastasis, the treatment ﬁeld was set to extend be-
yond the known extent of disease. From 167 patients evaluated
for GGH -401C>T genotypes, 101 completed 6 cycles of the chemo-
therapy treatment. Hematological toxicity was the main factor
causing treatment interruption.
2.3. Evaluation of chemotherapy response
Patients were followed on average for a period of 32 months. The re-
sponse to cisplatin was estimated by the change in tumor size, which
was measured by physical and CT exams performed before and after
completing the prescribed treatment. The longest diameter of the lesion
was measured. Using RECIST criteria, the response was graded as com-
plete response (cervical lesion eradication), partial response (at least a
30% decrease in the longest diameter of the cervical lesion), stable
disease (neither sufﬁcient shrinkage to qualify for partial response nor
sufﬁcient increase to qualify for progressive disease) andprogressive dis-
ease (at least a 20% increase in the longest diameter of the cervical
lesion). Patients with complete or partial responses were classiﬁed as
good responders and patients with stable or progressive disease were
regarded as poor responders.
2.4. Sample collection and genotyping
Genomic DNA was extracted from blood samples by using
QIAamp® DNA Blood Mini Kit (QIAGEN®). For the detection of the
GGH -401C>T polymorphism, we used real-time polymerase chain re-
action (PCR) by TaqMan allelic discrimination assay according to man-
ufacture instructions. Probes used were ﬂagged with VIC®/FAM™
dyers, respectively linked to the wild-type and the variant allele:
CTGGCCAACCCAGGTCCTCGAGAGG[A/G]GAGGTTGGGTGTCCCCGGCC
GAGTT. Results were analyzed on a sequence detection system ABI
7300, version 1.2.3 (Applied Biosystems, USA) Negative controls
were included in each run and 10% of the samples' genotyping was
repeated for quality control. Samples were tested in a blind fashion.
2.5. Statistical analyses
Analysis of data was performed using the computer software Sta-
tistical Package for Social Sciences (SPSS) for Windows (version 18.0).Difference in frequencies of the GGH genotypes between different
chemotherapy response groups were evaluated by χ2 test, consider-
ing pb0.05 statistically signiﬁcant. Overall survival was deﬁned as
the time, in months, between diagnosis and either death or time of
the last clinical evaluation. OS curves were plotted using the Kaplan–
Meier method and were compared with the log-rank test. Multivariate
analysis (Cox regression) was performed with variables considered im-
portant prognostic factors in cervical cancer, which were the tumor
stage, histology, the presence of lymph node metastasis and the geno-
type GGH -401CC.
3. Results
3.1. Patient characteristics
The median age of patients at diagnosis was 47 years with a mean
age of 48.58 years (SD=12.78). The FIGO stages of the enrolled pa-
tients were as follow: 13 patients with IB2, 4 patients with IIA, 43 pa-
tients with IIB, 24 patients with III and IV stages. Most patients (80%)
presented squamous cell carcinoma and no lymph node metastasis
(94%). All patients received cisplatin-based chemoradiotherapy.
From those, 71 patients carrying the CC genotype were good responders
and 5were poor responders. Frompatients carrying the CT/TT genotypes,
81were good responders and 10were poor responders (OR=0.741, 95%
IC 0.487-1.129; p=0.140). Sample characteristics are reported in Table 1.
3.2. SNP genotyping
We analyzed GGH -401C>T polymorphism genotypes using the
real-time PCR methodology. The genotype frequencies observed were
45.1% (78 cases) for CC genotype, 42.2% (73 cases) for CT heterozygous
genotype and 12.7% (22 cases) for TT genotype. The genotypic frequen-
cies were in genetic equilibrium according to the Hardy–Weinberg law
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tionally tested but no statistically signiﬁcant differences were observed
(data not shown).
3.3. Response to chemotherapy in relation to GGH -401C>T polymorphism
Regardingmean survival time, we used the Kaplan–Meiermethodol-
ogy to calculate the differences between the survival times of women
carrying the CC genotype and the CT/TT genotypes. A statistically signif-
icant association between the GGH -401C>T polymorphism and overall
survival was observed in the univariate analysis [survival time in
months/genotype: 91 for CC (95% CI 82,77 - 99,33) Vs 72 for CT/TT
(95% CI 60,80 - 82,68); p=0.035, log rank test]. Accordingly, the multi-
variate analysis (Cox regression) adjusted to tumor stage, histology and
the presence of lymph node metastasis showed that GGH genotypes
were signiﬁcantly linked to treatment response. Accordingly, individuals
carrying the T allele had 3 times more risk of death relatively to women
carrying the CC genotype (HR=3.036; CI 95% 1.032-8.934, p=0.044)
(Fig. 1).
4. Discussion
Although evidence suggests that folate deprivation acts synergistical-
ly with alkylating agents (Courtemanche et al., 2004; Novakovic et al.,
2006; Whiteside et al., 2006), the activation of compensatory mecha-
nisms leading to cell survival have been described. According to
(Hayashi et al., 2007), who studied folate depletion in colon cancer
cells, folate deprivation and disrupted one-carbon metabolism could be
compensated by adaptivemechanisms that enable cells tomaintain crit-
ical one-carbon metabolism reactions (Hayashi et al., 2007). The devel-
opment of a survival advantage was also observed in Chinese Hamster
Ovary cells resistant to the growth-limiting effects of folate depletion, en-
abling them to better withstand cisplatin cytotoxicity (Branda et al.,
1998). (Cole et al., 2001) also described compensatory changes suscepti-
ble of affecting drug sensitivity after GGH overexpression in MCF7 cells
(Cole et al., 2001).
Since the GGH -401C>T polymorphism leads to GGH overexpression,
we thought that an impairment in folatemetabolismmight activate com-
pensatory pathways involved in DNA repair andmaintenance of cell sur-
vival. According to ourmain hypothesis, the GGH -401C>T SNPmight be
involved in the development of cisplatin-based chemoradiotherapy re-
sistance. The fact cisplatin causes an increase in the intracellular levels
of 5,10-methylene-tetrahydrofolate and tetrahydrofolate, and enhancesFig. 1. Cox regression analysis of cervical cancer patients adjusted to tumor FIGO stage,
tumor histology and the presence of lymph node metastasis, according to GGH
-401C>T genotypes (HR=3.036; CI 95% 1.032-8.934, p=0.044).the gene expression of enzymes involved in dTMP synthase cycle sup-
ports our suggestion (Lu et al., 1988; Scanlon and Kashani-Sabet, 1988;
Whiteside et al., 2006).
According to our results, the CC carriers had a signiﬁcantly
higher overall survival than the T allele carriers [survival time in
months/genotype: 91 for CC (95% CI 82,77 - 99,33) Vs 72 for CT/TT
(95% CI 60,80 - 82,68); p=0.035, log rank test]. A multivariate analysis
supported this observation, showing that patients carrying the T allele
had 3 times more risk of death relatively to women carrying the CC ge-
notype (HR=3.036; CI 95% 1.032-8.934, p=0.044) (Fig. 1). However, it
is important to note that folate depletion poses different metabolic
stresses in cells depending on the cell type,whichwill result in different
adaptive regulation of folatemetabolism enzymes (Hayashi et al., 2007;
Novakovic et al., 2006). A cDNA microarray analysis of a human squa-
mous cell carcinoma cell line treated with cisplatin for 5 days accord-
ingly revealed a 2.55 signal ratio for GGH, suggesting its involvement
in cisplatin cytotoxicity (Yatomi et al., 2007).
5. Conclusions
On the light of these results we might suggest that this polymor-
phism might be a predictive factor of the outcome of cervical carcino-
ma treated with cisplatin-based chemoradiotherapy, though future
and larger studies would be necessary to conﬁrm it. As GGH is a non-
speciﬁc enzyme, whose expression is dependent on the analyzed tissue,
it might not be appropriate to draw a generalized conclusion regarding
other cancer models, whose folate requirements for growth are differ-
ent. The fact we could not study other genes involved in folate metabo-
lism, DNA repair or treatment response is one drawback of this study.
Although an increase in neoadjuvant cisplatin-based chemotherapy
response for cervical cancer patients carrying the CC genotype has al-
readybeenobservedby (Chung et al., 2006), to the best of our knowledge
there are currently no published studies on the relationship between
GGH -401C>T polymorphism and cervical cancer chemoradiotherapy
response.
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